Inside informationEnglish
Valneva Reports Positive Six-Month Antibody Persistence and Safety Phase 2 Results in Children for its Single-Shot Chikungunya Vaccine IXCHIQ®
The file is served by the AMF. We do not host a copy.
Document type
- Issuer
- Valneva SE
- Filed
- 05/06/2025, 17:45
- Document type
- Inside information
- AMF sub-type
- Informations privilégiées
- Language
- English
- AMF reference
- 111095_20250605